PTGIR and pulmonary arterial hypertension: The currently available five drug classes, namely PDE5Is, soluble guanylate cyclase inhibitors, prostacyclin analogs, prostacyclin receptor agonists, and ERAs, have been proven as beneficial as initial therapy either as monotherapy or in combination in recent long-term trials evidenced by progression-free survival of PAH patients [31].